Clinical Trials Directory

Trials / Completed

CompletedNCT05199792

Efficacy of Gadoterate Meglumine in Diagnosis of Vascular Diseases Using MRA MRA

Efficacy of Gadoterate Meglumine in Diagnosis of Vascular Diseases Using MRA

Status
Completed
Phase
Study type
Observational
Enrollment
65 (actual)
Sponsor
Northwestern University · Academic / Other
Sex
All
Age
18 Years – 89 Years
Healthy volunteers
Accepted

Summary

The purpose of this study is to compare magnetic resonance angiography (MRA) using gadoterate meglumine to clinically obtained MRA using gadobutrol. The specific aims are to show: 1. Carotid, chest, and abdomenal MRA with gadoterate meglumine has a comparable image quality and diagnostic confidence to MRA using gadobutrol. 2. Carotid, chest, and abdomenal MRA with gadoterate meglumine has a comparable accuracy for vascular lesion and stenosis detection compared to MRA using gadobutrol.

Detailed description

In this study, we will assess the image quality and accuracy of MRA studies acquired using these two contrast agents. In the cases where Digital Subtraction Angiography (DSA) or CT angiography images are available, the results of the study using both contrast agents will be compared to the DSA or CTA findings. All MRA images will be assessed independently by two readers. The readers will be blinded to the clinical symptoms, contrast agent and DSA/CTA results. A five-level system rating for image quality of each arterial segment will be used (1 = non-diagnostic images, 2 = poor image quality, significant blurring/artefacts, diagnosis suspected but not established, 3 = fair quality with established diagnosis, 4=good quality with definite diagnosis, minimal blurring/artefacts, 5 = sharply defined borders, excellent quality image information). Vascular lesions will also be graded on a 1-5 scale. Vessel segment stenoses will be graded using a five-point grading scale as follows: (1) normal; (2) mild (\<50% diameter stenosis); (3) moderate (50% to 74%), severe (75% to 99%); and (5) total occlusion. Grades 1 and 2 will be considered insignificant, while grades 3 to 5 will be interpreted as significant for diagnostic accuracy testing.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTDotarem(Dotarem) (0.4 ml/kg (0.2 mmol/kg))

Timeline

Start date
2017-06-02
Primary completion
2019-12-31
Completion
2020-01-01
First posted
2022-01-20
Last updated
2022-01-20

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT05199792. Inclusion in this directory is not an endorsement.